Trial Profile
A Study to Evaluate the Pharmacokinetics of Tadalafil Administered Once Daily in Japanese and Non-Japanese Subjects With Benign Prostatic Hyperplasia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tadalafil (Primary)
- Indications Benign prostatic hyperplasia
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 21 Nov 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004062).
- 15 May 2012 Actual number of patients changed from 12 to 24 as reported by ClinicalTrials.gov.
- 11 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.